Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1988 1
1989 2
1991 3
1992 3
1993 3
1995 2
1996 3
1997 3
1998 1
1999 3
2000 1
2002 1
2003 1
2004 1
2005 3
2006 3
2008 1
2009 7
2010 5
2011 5
2012 5
2014 1
2015 2
2016 5
2017 8
2018 2
2019 6
2020 4
2021 7
2022 8
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Keenan TDL, Oden NL, Agrón E, Clemons TE, Henning A, Wong WT, Chew EY. Keenan TDL, et al. Among authors: oden nl. Ophthalmol Retina. 2022 Apr;6(4):334-335. doi: 10.1016/j.oret.2021.12.002. Ophthalmol Retina. 2022. PMID: 35393078 No abstract available.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. Among authors: oden nl. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. Among authors: oden nl. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
SCORE2 Report 2: Study Design and Baseline Characteristics.
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Figueroa M, Dugel PU; SCORE2 Investigator Group. Scott IU, et al. Among authors: oden nl. Ophthalmology. 2017 Feb;124(2):245-256. doi: 10.1016/j.ophtha.2016.09.038. Epub 2016 Nov 15. Ophthalmology. 2017. PMID: 27863843 Free PMC article. Clinical Trial.
Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Keppler-Noreuil KM, Lozier J, Oden N, Taneja A, Burton-Akright J, Sapp JC, Biesecker LG. Keppler-Noreuil KM, et al. Among authors: oden n. Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):571-581. doi: 10.1002/ajmg.c.31735. Epub 2019 Sep 6. Am J Med Genet C Semin Med Genet. 2019. PMID: 31490637 Free PMC article.
103 results